CCantor NNVIDIA · NVDA

Cantor Fitzgerald Maintains Overweight on NVIDIA, $240 PT

Aug 28, 2025· 1 min read· Reproduced verbatim
Rating
Buy
Price target
$240
Previous
Implied upside
+32%

Cantor Fitzgerald analyst C.J. Muse reiterated on August 28, 2025, an ‘Overweight’ rating and $240 price target on Nvidia.

“While the October revenue guide of $54.0B beat consensus of $52.6B, the buyside was hoping for ~$1B more, causing a modest sell-off overnight.

As for our view, rise up tomorrow morning, smile with the rising sun, and don’t worry about a thing “cause every little thing (is) gonna be alright”.

NVDA is currently sold out of Blackwell and the October Q outlook includes zero China H20 revenues given geopolitical uncertainty, though mgmt. suggested their ability to ship $2-5B in the Q.

As this gets resolved, look for upside into 2HCY25 and beyond with China today completely de-risked.

Very importantly, the Blackwell Ultra ramp is just getting started (generating tens of billions of revenues in the July Q), and we continue to see NVDA on a path to ship 5.5M GPUs in CY25, coupled with meaningful Networking attach that continues to support a stretch goal of $200B in Data Center revenues in CY25 (vs. current consensus of $178B and notwithstanding headwinds from China).

Looking ahead, we look for a solid hand-off from Blackwell Ultra to Rubin in 2HCY26 (mgmt. indicated ramp on track, recently taped out 6 new chips at TSMC) as the company scales to support an estimated $3-4 trillion AI infrastructure buildout through the end of the decade and pushing NVDA to a path to $300B in Data Center revenues in CY26E (which would support our highlighted stretch EPS goal of $8.00).”

Disclaimer
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.

This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.

Share

Share on
Price Target is an archive of Wall Street analyst research, published for informational purposes only. Nothing on this site is investment advice, a recommendation, or an offer to buy or sell any security. Analyst ratings and price targets are the opinions of the issuing firms, not of Price Target. Always do your own research or consult a licensed financial adviser.